Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

Journal of Clinical Oncology

Volumn 28, Issue 7, 2010, Pages 1215-1223

  Makhija, Sharmila ^a   Amler, Lukas C ^a   Glenn, Dana ^a   Ueland, Frederick R ^a   Gold, Michael A ^a   Dizon, Don S ^a   Paton, Virginia ^a   Lin, Chin Yu ^a   Januario, Thomas ^a   Ng, Kimmie ^a   Strauss, Andreas ^a   Kelsey, Stephen ^a   Sliwkowski, Mark X ^a   Matulonis, Ursula ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEMCITABINE; MESSENGER RNA; PERTUZUMAB; PLACEBO; PLATINUM; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACKACHE; CANCER GROWTH; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER; RHINORRHEA; STOMATITIS; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; MULTICENTER STUDY; OVARY TUMOR; PERITONEUM TUMOR; UTERINE TUBE TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, MESSENGER;

EID: 77949900758     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.3354     Document Type: Article

References (26)

1. Carmichael J: The role of gemcitabine in the treatment of other tumours. Br J Cancer 78:21-25, 1998
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
3. Pectasides D, Psyrri A, Pectasides M, et al: Optimal therapy for platinum-resistant recurrent ovarian cancer: Doxorubicin, gemcitabine or topotecan? Expert Opin Pharmacother 7:975-987, 2006 (Pubitemid 43949937)
4. Armstrong DK: Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist 5:20-28, 2002 (suppl)
5. Lorusso D, Ferrandina G, Fanfani F, et al: Investigational agents against platinum-resistant ovarian cancer. Expert Opin Investig Drugs 16:325-336, 2007 (Pubitemid 46394857)
6. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004 (Pubitemid 38482068)
7. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002 (Pubitemid 41039113)
8. Gelman K, Fumoleau P, Verma S, et al: Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 26:47s, 2008 (suppl; abstr 1026)
9. Malik I, Hecht JR, Patnaik A, et al: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 23:251s, 2005 (suppl; abstr 3520)
10. Takai N, Jain A, Kawamata N, et al: 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104:2701-2708, 2005 (Pubitemid 41798280)
11. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999 (Pubitemid 29415219)
12. Bookman MA, Darcy KM, Clarke-Pearson D, et al: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283-290, 2003 (Pubitemid 46606157)
13. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, et al: Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32:180-190, 2006
14. Gordon MS, Matei D, Aghajanian C, et al: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324-4332, 2006 (Pubitemid 46630791)
15. Markman M, Webster K, Zanotti K, et al: Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90:593-606, 2003
16. D'Agostino G, Amant F, Berteloot P, et al: Phase II study of gemcitabine in recurrent platinumand paclitaxel-resistant ovarian cancer. Gynecol Oncol 88:266-269, 2003 (Pubitemid 36331977)
17. Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′2′-difluorodeoxycytidine) in previous treated ovarian cancer patients. J Natl Cancer Inst 86:1530-1533, 1994 (Pubitemid 24330217)
18. Vergote I, Rustin GJ, Eisenhauer EA, et al: Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]: Gynecologic Cancer Intergroup. J Natl Cancer Inst 92:1534-1535, 2000
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. National Cancer Institute: Definitions for CTCAE Version 3.0. http://ctep.info.nih.gov/
21. Cronin M, Pho M, Dutta D, et al: Measurement of gene expression in archival paraffinembedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164:35-42, 2004 (Pubitemid 38364587)
22. Brown AP, Carlson TC, Loi CM, et al: Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol 59:671-679, 2007 (Pubitemid 46295133)
23. Boyd ZS, Wu QJ, O'Brien C, et al: Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther 7:3695-3706, 2008
24. Folkes AJ, Ahmadi K, Alderton WK, et al: The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 51:5522-5532, 2008
25. Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441, 2007 (Pubitemid 46160912)
26. Sakai K, Yokote H, Murakami-Murofushi K, et al: Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci 98:1498-1503, 2007 (Pubitemid 47241776)